Details of the Drug Combination

General Information of Drug Combination (ID: DCJR1P3)

Drug Combination Name
Miglustat Pepstatin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Miglustat   DM5J64S Pepstatin   DM9S1EA
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 2.95
Bliss Independence Score: 2.95
Loewe Additivity Score: 20.21
LHighest Single Agent (HSA) Score: 20.21

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Miglustat
Disease Entry ICD 11 Status REF
Niemann-Pick disease type C N.A. Approved [2]
Type 1 gaucher disease 5C56.0Y Approved [3]
Gaucher disease 5C56.0Y Investigative [2]
Miglustat Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ceramide glucosyltransferase (UGCG) TTPHEX3 CEGT_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Miglustat Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Increases Activity [6]
------------------------------------------------------------------------------------
Indication(s) of Pepstatin
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Terminated [4]
Pepstatin Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) TT7EASG Q9N6S8_PLAFA Inhibitor [7]
Plasmodium Plasmepsin 2 (Malaria PLA2) TTXMNHO PLM2_PLAFA Inhibitor [8]
Plasmodium Plasmepsin 1 (Malaria PLA1) TTH9VL3 PLM1_PLAFA Inhibitor [8]
Plasmodium Cysteine protease falcipain (Malaria CPF) TTJNPTK NOUNIPROTAC Inhibitor [8]
------------------------------------------------------------------------------------
Pepstatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cathepsin D (CTSD) OTQZ36F3 CATD_HUMAN Decreases Activity [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Miglustat FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4841).
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004280)
5 Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54.
6 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
7 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
8 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
9 Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ. 2001 May;8(5):477-85. doi: 10.1038/sj.cdd.4400843.